Phase 1 B-cell Acute Lymphoblastic Leukemia Clinical Trials
26 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 26 trials
Recruiting
Phase 1Phase 2
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled80 locationsNCT06137118
Recruiting
Phase 1Phase 2
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Amgen104 enrolled4 locationsNCT07134088
Recruiting
Phase 1Phase 2
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver45 enrolled1 locationNCT04544592
Recruiting
Phase 1Phase 2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
B-cell Acute Lymphoblastic Leukemia
Merck Sharp & Dohme LLC90 enrolled67 locationsNCT06395103
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1Phase 2
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca83 enrolled26 locationsNCT07109219
Recruiting
Phase 1
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 1Phase 2
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+8 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 1Phase 2
Co-administration of CART22-65s and huCART19 for B-ALL
B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD93 enrolled1 locationNCT05674175
Recruiting
Phase 1
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic Leukemia
Beijing GoBroad Hospital48 enrolled1 locationNCT06326008
Recruiting
Phase 1
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
B-cell Acute Lymphoblastic Leukemia
Children's Hospital Medical Center, Cincinnati28 enrolled1 locationNCT06863259
Recruiting
Phase 1Phase 2
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd46 enrolled12 locationsNCT06580301
Recruiting
Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaSmall Lymphocytic Lymphoma+1 more
Imugene Limited135 enrolled23 locationsNCT03666000
Recruiting
Phase 1
Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
B-cell Acute Lymphoblastic Leukemia
Bambino Gesù Hospital and Research Institute24 enrolled1 locationNCT06080191
Recruiting
Phase 1
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
B-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver53 enrolled1 locationNCT06559189
Recruiting
Phase 1
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University4 enrolled1 locationNCT06507514
Recruiting
Phase 1
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
B-cell Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) in Lymphoid Blast CrisisPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Marlise Luskin, MD40 enrolled4 locationsNCT03595917
Recruiting
Phase 1Phase 2
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
B-cell Acute Lymphoblastic Leukemia
Cellectis S.A.52 enrolled19 locationsNCT04150497
Recruiting
Phase 1Phase 2
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.47 enrolled9 locationsNCT05667506
Recruiting
Phase 1
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.33 enrolled8 locationsNCT06927466